July 19, 2022
1 min watch
Save
VIDEO: No survival benefit of resecting asymptomatic primary tumor
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video Michael Cecchini, MD discussed study presented at ASCO that "puts to rest" whether asymptomatic primary tumors in patients with metastatic colorectal cancer should be resected.
The multicent, randomized, controlled, superiority trial with a two-group parallel design evaluated colon cancer with synchronous unresectable tumors and found that resection of metastases before chemotherapy did not increase overall survival.
"Asymptomatic primary tumors should be left in place and we should focus on systemic therapy," Cecchini assistant professor of medical ncology at Yale School of Medicine, said.
Published by:
Sources/Disclosures
Collapse
Source:
Rahbari N, et al. Abstract LBA3507. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Disclosures:
Cecchini reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.